<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098198</url>
  </required_header>
  <id_info>
    <org_study_id>BioMetabol</org_study_id>
    <nct_id>NCT04098198</nct_id>
  </id_info>
  <brief_title>Biomarkers for Inborn Errors of Metabolism</brief_title>
  <acronym>BioMetabol</acronym>
  <official_title>Biomarkers for Inborn Errors of Metabolism: An International, Multicenter, Observational, Longitudinal Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CENTOGENE GmbH Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CENTOGENE GmbH Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      International, multicenter, observational, longitudinal study to identify or monitor Inborn&#xD;
      Error of Metabolism disease biomarkers and to explore the clinical robustness, specificity,&#xD;
      and long-term variability of these biomarkers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inborn Errors of Metabolism (IEM) are a large group of congenital metabolic disorders,&#xD;
      resulting from the absence or abnormality of an enzyme or its cofactor and leading to either&#xD;
      accumulation or deficiency of a specific metabolite. More than 800 IEM have been described in&#xD;
      the literature, with a widely accepted classification focusing on the main substrate which is&#xD;
      affected.&#xD;
&#xD;
      Clinical phenotypes of IEM are broad and often non-specific, mimicking more common&#xD;
      conditions, and the onset of symptoms can occur at any age, from fetus to adult. Peroxisomal&#xD;
      and lysosomal storage disorders, for example, often have characteristic clinical features and&#xD;
      permanent, progressive symptoms that are independent of triggering events (e.g. anemia,&#xD;
      thrombocytopenia, and hepatomegaly in a child of Ashkenazi-Jewish ancestry is suggestive of&#xD;
      Gaucher disease) 6. More common findings include hypoketotic hypoglycemia, lactic acidosis,&#xD;
      metabolic acidosis, ketosis, hyperammonemia, or other metabolic acidosis in combination with&#xD;
      hyperammonemia.&#xD;
&#xD;
      The goal of treatment for participants with IEM are the prevention of further accumulation of&#xD;
      harmful substances, correction of metabolic abnormalities, and elimination of toxic&#xD;
      metabolites. Most participants suffering for rare metabolic diseases start with very severe&#xD;
      phenotypes and with rapid progression of the disease that often leads to irreversible damage&#xD;
      of their organs. A quick diagnosis is necessary for urgent treatment.&#xD;
&#xD;
      Biomarkers serve as measurable indicators of normal biological or pathological processes.&#xD;
      They are typically directly linked to genetic variants in specific genes and can predict,&#xD;
      diagnose, monitor and assess the severity of a disease.&#xD;
&#xD;
      CENTOGENE has an outstanding experience regarding the investigation and development of&#xD;
      biomarkers for IEM. Given the large amount of participants CENTOGENE is facing and&#xD;
      diagnosing, it has a big repertoire of samples to use for the biomarker characterization.&#xD;
      This led for example to the identification of Lyso-Gb1 as a novel biomarker for Gaucher&#xD;
      disease orLyso-SM509 for Niemann-Pick Disease. The established workflows and gained knowledge&#xD;
      for the biomarker development at CENTOGENE will enhance the search for new biomarkers of&#xD;
      other IEM.&#xD;
&#xD;
      It is the goal of this study to identify, validate, and monitor biochemical markers from&#xD;
      affected participants for Inborn Errors of Metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of biomarkers for Inborn Errors of Metabolism</measure>
    <time_frame>2 years</time_frame>
    <description>All samples will be analyzed for the identification of biomarker/s via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exploring the clinical robustness, specificity, and long-term variability of biomarkers for Inborn Errors of Metabolism</measure>
    <time_frame>2 years</time_frame>
    <description>Samples will be analyzed for the identified biomarker candidates via Liquid Chromatography Multiple Reaction-monitoring Mass Spectrometry (LC/MRM-MS) and compared to merged control, in order to establish the disease-specific biomarker/s. The LC/MRM-MS is performed on an ABSciex 6500 triple quadrupole mass spectrometer, coupled with a Waters Acquity UPLC.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Inborn Errors of Metabolism</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Participants with an Inborn Error of Metabolism</arm_group_label>
    <description>Participants diagnosed with an Inborn Error of Metabolism aged between 2 months to 50 years</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sample applied on the Dry Blood Spot (DBS) Filtercard (CentocardÂ®)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with an Inborn Error of Metabolism&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent is obtained from the participant or from their parent/legal guardian,&#xD;
             before any study related procedures&#xD;
&#xD;
          -  The participant aged between 2 months old and 50 years old&#xD;
&#xD;
          -  The diagnosis of an Inborn Error of Metabolism is genetically confirmed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  The participant is younger than 2 months old or older than 50 years old&#xD;
&#xD;
          -  The diagnosis of an Inborn Error of Metabolism (IEM) is not genetically confirmed&#xD;
&#xD;
          -  Previously enrolled in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Peter Bauer, Prof. Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Centogene GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sana Iftikhar</last_name>
    <phone>+49 381 80113 544</phone>
    <email>sana.iftikhar@centogene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Center Mother Teresa</name>
      <address>
        <city>Tirana</city>
        <zip>10001</zip>
        <country>Albania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paskal Cullufi, MD</last_name>
      <phone>+35 5672043840</phone>
      <email>paskalcullufi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paskal Cullufi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Clinical Genetics, Alexandria University Children's Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iman Marzouk, MD</last_name>
      <phone>+20 1223243407</phone>
      <email>drimanmarzouk@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Iman Marzouk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Pediatrics, Alexandria University Children's Hospital</name>
      <address>
        <city>Alexandria</city>
        <zip>21131</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tarek Elsayed Omar, MD</last_name>
      <phone>+20 2035826512</phone>
      <email>Tarek.Omar@alexmed.edu.eg</email>
    </contact>
    <investigator>
      <last_name>Tarek Elsayed Omar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Medical Genetics ,Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <phone>+201060260052</phone>
      <email>elsayed683@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Solaf Mohamed El Sayed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Omnia El Rashidy, MD</last_name>
      <phone>+20 (0)1222164876</phone>
      <email>omniarashidy@hotmail.com</email>
    </contact>
    <contact_backup>
      <phone>+20 (0)0224512900</phone>
      <email>draghdaz@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Omnia El Rashidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Faculty of Medicine, Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hoda Tomoum, MD</last_name>
      <phone>+20 (0)0224156526</phone>
      <email>hodatomoum@gmail.com</email>
    </contact>
    <contact_backup>
      <email>mennahshata@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Hoda Tomoum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatrics Departmnet, Tanta University</name>
      <address>
        <city>Tanta</city>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heba Dawoud, MD</last_name>
      <phone>+20 1094623100</phone>
      <email>hebadawoud173@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Heba Dawoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Molecular and Medical Genetics , Tbilisi State Medical University</name>
      <address>
        <city>Tbilisi</city>
        <zip>0177</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tinatin Tkemaladze, MD</last_name>
      <phone>+99 5032917304</phone>
      <email>tikatkem@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tinatin Tkemaladze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amrita Institute of Medical Sciences</name>
      <address>
        <city>Kerola</city>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <phone>+91 (0)4842851234</phone>
      <email>sheelanampoothiri@aims.amrita.edu</email>
    </contact>
    <investigator>
      <last_name>Sheela Nampoothiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's hospital, Vilnius University Hospital Santaros klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>O8406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <phone>+37 (0)063009244</phone>
      <email>rimante.cerkauskiene@santa.lt</email>
    </contact>
    <investigator>
      <last_name>Rimante Cerkauskiene, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Departmnet of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health</name>
      <address>
        <city>Lahore</city>
        <zip>54600</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huma Cheema, MD</last_name>
      <phone>+92 3009447550</phone>
      <email>pedgilahore@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Huma Cheema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emergency Hospital for Children &quot;Louis Turcanu&quot;</name>
      <address>
        <city>TimiÅoara</city>
        <zip>300011</zip>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adela Chirita, MD</last_name>
      <phone>+40 724369599</phone>
      <email>adela.chirita@umft.ro</email>
    </contact>
    <investigator>
      <last_name>Adela Chirita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lady Ridgeway Hospital for Children</name>
      <address>
        <city>Colombo</city>
        <zip>00800</zip>
        <country>Sri Lanka</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eresha Jasinge, MD</last_name>
      <phone>+94 (0)712793328</phone>
      <email>eresha.jasinge@gmail.com</email>
    </contact>
    <contact_backup>
      <phone>+94 (0)714040998</phone>
      <email>chempath.lrh@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eresha Jasinge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Albania</country>
    <country>Egypt</country>
    <country>Georgia</country>
    <country>India</country>
    <country>Lithuania</country>
    <country>Pakistan</country>
    <country>Romania</country>
    <country>Sri Lanka</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
    <country>Morocco</country>
  </removed_countries>
  <link>
    <url>https://www.centogene.com/</url>
    <description>CENTOGENE is a rare disease company focused on transforming clinical, genetic, and biochemical data into medical solutions for Patients</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 23, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>June 24, 2021</last_update_submitted>
  <last_update_submitted_qc>June 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inborn Error of Metabolism</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

